CR20210483A - Polvo de aceite de cannabis formulado por nanoemulsificación, métodos de producción y usos de los mismos - Google Patents
Polvo de aceite de cannabis formulado por nanoemulsificación, métodos de producción y usos de los mismosInfo
- Publication number
- CR20210483A CR20210483A CR20210483A CR20210483A CR20210483A CR 20210483 A CR20210483 A CR 20210483A CR 20210483 A CR20210483 A CR 20210483A CR 20210483 A CR20210483 A CR 20210483A CR 20210483 A CR20210483 A CR 20210483A
- Authority
- CR
- Costa Rica
- Prior art keywords
- methods
- nanoemulsifycation
- producing
- cannabis oil
- oil powder
- Prior art date
Links
- 240000004308 marijuana Species 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000843 powder Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229930003827 cannabinoid Natural products 0.000 abstract 1
- 239000003557 cannabinoid Substances 0.000 abstract 1
- 239000006185 dispersion Substances 0.000 abstract 1
- 239000007908 nanoemulsion Substances 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Replacement Of Web Rolls (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Psychology (AREA)
Abstract
La invención describe una formulación solida dispersable en agua particular de un cannabinoide o un extracto de cannabis, en donde se encuentran presentes en forma de nanoemulsión, y al dispersarse en agua dicha formulación produce nanopartículas (gotita de un tamaño submicrónico) con un tamaño promedio de hasta aproximadamente 500 nm. La presente exposición se refiere además a métodos para su elaboración, así como a aplicaciones terapéuticas en seres humanos para tratar trastornos y una aplicación más amplia para una variedad de afecciones médicas
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062983541P | 2020-02-28 | 2020-02-28 | |
US202063007333P | 2020-04-08 | 2020-04-08 | |
US202063040484P | 2020-06-17 | 2020-06-17 | |
US202063072790P | 2020-08-31 | 2020-08-31 | |
US202063126492P | 2020-12-16 | 2020-12-16 | |
PCT/US2021/020153 WO2021174164A1 (en) | 2020-02-28 | 2021-02-28 | Compounds and methods for modulating splicing |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20210483A true CR20210483A (es) | 2022-11-25 |
Family
ID=75143749
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20220484A CR20220484A (es) | 2020-02-28 | 2021-02-28 | Amidas heterocíclicas y su uso para modular el empalme |
CR20210483A CR20210483A (es) | 2020-02-28 | 2021-02-28 | Polvo de aceite de cannabis formulado por nanoemulsificación, métodos de producción y usos de los mismos |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20220484A CR20220484A (es) | 2020-02-28 | 2021-02-28 | Amidas heterocíclicas y su uso para modular el empalme |
Country Status (14)
Country | Link |
---|---|
US (1) | US20230365566A1 (es) |
EP (3) | EP4110464A1 (es) |
JP (2) | JP2023515621A (es) |
KR (2) | KR20220158238A (es) |
CN (2) | CN115485025A (es) |
AU (2) | AU2021228284A1 (es) |
BR (2) | BR112022017188A2 (es) |
CA (2) | CA3169691A1 (es) |
CL (2) | CL2022002342A1 (es) |
CO (2) | CO2022013827A2 (es) |
CR (2) | CR20220484A (es) |
IL (2) | IL295957A (es) |
MX (2) | MX2022010683A (es) |
WO (3) | WO2021174164A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2587457B (en) | 2017-08-04 | 2022-06-01 | Skyhawk Therapeutics Inc | Methods and compositions for modulating splicing |
MX2022013856A (es) | 2020-05-13 | 2023-04-05 | Chdi Foundation Inc | Moduladores htt para tratar la enfermedad de huntington. |
WO2023034811A1 (en) | 2021-08-30 | 2023-03-09 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
WO2023034812A1 (en) | 2021-08-30 | 2023-03-09 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
CA3238090A1 (en) * | 2021-11-17 | 2023-05-25 | Chdi Foundation, Inc. | Htt modulators for treating huntington's disease |
WO2023244996A2 (en) * | 2022-06-15 | 2023-12-21 | Ptc Therapeutics, Inc. | Heterocyclic and heteroaryl compounds for treating huntington's disease |
WO2024086570A1 (en) | 2022-10-17 | 2024-04-25 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
WO2024086569A1 (en) | 2022-10-17 | 2024-04-25 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4809656B2 (ja) * | 2005-09-29 | 2011-11-09 | 富士フイルム株式会社 | ナフタロシアニン色素およびその製造方法 |
TW200808325A (en) * | 2006-07-06 | 2008-02-16 | Astrazeneca Ab | Novel compounds |
JP5274460B2 (ja) * | 2006-08-08 | 2013-08-28 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | E1活性化酵素のインヒビターとして有用なヘテロアリール化合物 |
WO2008040951A1 (en) * | 2006-10-03 | 2008-04-10 | Astrazeneca Ab | Compounds |
EP2282995B1 (en) * | 2008-05-23 | 2015-08-26 | Novartis AG | Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors |
AU2010253790A1 (en) * | 2009-05-29 | 2011-12-15 | Merck Sharp & Dohme Corp. | Antiviral compounds composed of three aligned aryl moieties to treat diseases such as Hepatitis C |
CN102020643A (zh) * | 2009-09-22 | 2011-04-20 | 上海恒瑞医药有限公司 | 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用 |
TW201202230A (en) * | 2010-05-24 | 2012-01-16 | Mitsubishi Tanabe Pharma Corp | Novel quinazoline compound |
DK2812004T3 (en) | 2012-02-10 | 2018-10-15 | Ptc Therapeutics Inc | COMPOUNDS FOR TREATMENT OF SPINAL MUSCLE DROPHY |
CN104271568B (zh) * | 2012-05-09 | 2016-05-04 | 硕腾服务有限责任公司 | 作为抗寄生虫剂的氮杂环丁烷衍生物 |
MY174339A (en) | 2012-08-13 | 2020-04-09 | Novartis Ag | 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions |
CN105377851B (zh) * | 2013-03-11 | 2018-07-20 | 密执安州立大学董事会 | Bet布罗莫结构域抑制剂和使用这些抑制剂的治疗方法 |
KR20140125061A (ko) * | 2013-04-18 | 2014-10-28 | (주)경인양행 | 유기발광 화합물 및 이를 포함하는 유기전계발광소자 |
WO2016004254A1 (en) * | 2014-07-01 | 2016-01-07 | The Regents Of The University Of California | Combined modulation of ire1 |
CN104341403B (zh) * | 2014-10-10 | 2016-06-22 | 山东盛华电子新材料有限公司 | 一种2,5-二杂环取代萘基噁烷衍生物及其制备方法 |
EP3256126B1 (en) | 2015-02-09 | 2024-03-27 | F. Hoffmann-La Roche AG | Compounds for the treatment of cancer |
WO2016169504A1 (zh) * | 2015-04-24 | 2016-10-27 | 广州再极医药科技有限公司 | 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用 |
EP3310169B1 (en) | 2015-05-30 | 2023-05-17 | PTC Therapeutics, Inc. | Methods for modulating rna splicing |
ES2879995T3 (es) | 2015-12-10 | 2021-11-23 | Ptc Therapeutics Inc | Métodos para el tratamiento de la enfermedad de Huntington |
WO2017147328A1 (en) * | 2016-02-23 | 2017-08-31 | Portola Pharmaceuticals, Inc. | Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9) |
WO2018098446A1 (en) | 2016-11-28 | 2018-05-31 | Ptc Therapeutics, Inc | Methods for modulating rna splicing |
EA202090034A1 (ru) | 2017-06-14 | 2020-04-16 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Способы модификации сплайсинга рнк |
GB2587457B (en) | 2017-08-04 | 2022-06-01 | Skyhawk Therapeutics Inc | Methods and compositions for modulating splicing |
CN111373057A (zh) | 2017-09-25 | 2020-07-03 | 斯基霍克疗法公司 | 用于筛选和鉴定剪接调节剂的方法和组合物 |
JP2021521200A (ja) | 2018-04-10 | 2021-08-26 | スカイホーク・セラピューティクス・インコーポレーテッド | 癌の処置のための化合物 |
CA3105174A1 (en) * | 2018-06-27 | 2020-01-02 | Reborna Biosciences, Inc. | Prophylactic or therapeutic agent for spinal muscular atrophy |
CN109180690A (zh) * | 2018-10-15 | 2019-01-11 | 烟台显华化工科技有限公司 | 一类用作蓝色荧光材料的氮杂芳香化合物及其应用 |
-
2021
- 2021-02-28 US US17/802,719 patent/US20230365566A1/en active Pending
- 2021-02-28 AU AU2021228284A patent/AU2021228284A1/en active Pending
- 2021-02-28 IL IL295957A patent/IL295957A/en unknown
- 2021-02-28 WO PCT/US2021/020153 patent/WO2021174164A1/en active Application Filing
- 2021-02-28 WO PCT/US2021/020154 patent/WO2021174165A1/en active Application Filing
- 2021-02-28 BR BR112022017188A patent/BR112022017188A2/pt unknown
- 2021-02-28 CN CN202180031467.0A patent/CN115485025A/zh active Pending
- 2021-02-28 MX MX2022010683A patent/MX2022010683A/es unknown
- 2021-02-28 CA CA3169691A patent/CA3169691A1/en active Pending
- 2021-02-28 MX MX2022010684A patent/MX2022010684A/es unknown
- 2021-02-28 JP JP2022552209A patent/JP2023515621A/ja active Pending
- 2021-02-28 JP JP2022552208A patent/JP2023515620A/ja active Pending
- 2021-02-28 BR BR112022017210A patent/BR112022017210A2/pt unknown
- 2021-02-28 CR CR20220484A patent/CR20220484A/es unknown
- 2021-02-28 KR KR1020227033663A patent/KR20220158238A/ko unknown
- 2021-02-28 EP EP21713823.9A patent/EP4110464A1/en active Pending
- 2021-02-28 EP EP21713822.1A patent/EP4110785A1/en active Pending
- 2021-02-28 WO PCT/US2021/020152 patent/WO2021174163A1/en unknown
- 2021-02-28 KR KR1020227033660A patent/KR20220159386A/ko unknown
- 2021-02-28 CR CR20210483A patent/CR20210483A/es unknown
- 2021-02-28 CN CN202180030671.0A patent/CN115515679A/zh active Pending
- 2021-02-28 IL IL295956A patent/IL295956A/en unknown
- 2021-02-28 AU AU2021228767A patent/AU2021228767A1/en active Pending
- 2021-02-28 CA CA3169709A patent/CA3169709A1/en active Pending
- 2021-02-28 EP EP21713824.7A patent/EP4110459A1/en active Pending
-
2022
- 2022-08-26 CL CL2022002342A patent/CL2022002342A1/es unknown
- 2022-08-26 CL CL2022002341A patent/CL2022002341A1/es unknown
- 2022-09-27 CO CONC2022/0013827A patent/CO2022013827A2/es unknown
- 2022-09-27 CO CONC2022/0013832A patent/CO2022013832A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2023515621A (ja) | 2023-04-13 |
BR112022017188A2 (pt) | 2022-11-08 |
CN115485025A (zh) | 2022-12-16 |
CA3169691A1 (en) | 2021-09-02 |
CO2022013832A2 (es) | 2022-10-31 |
US20230365566A1 (en) | 2023-11-16 |
EP4110785A1 (en) | 2023-01-04 |
EP4110459A1 (en) | 2023-01-04 |
BR112022017210A2 (pt) | 2022-10-25 |
KR20220159386A (ko) | 2022-12-02 |
CN115515679A (zh) | 2022-12-23 |
CO2022013827A2 (es) | 2022-10-31 |
MX2022010684A (es) | 2023-01-19 |
WO2021174163A1 (en) | 2021-09-02 |
KR20220158238A (ko) | 2022-11-30 |
EP4110464A1 (en) | 2023-01-04 |
AU2021228284A1 (en) | 2022-09-29 |
WO2021174165A1 (en) | 2021-09-02 |
CA3169709A1 (en) | 2021-09-02 |
IL295956A (en) | 2022-10-01 |
AU2021228767A1 (en) | 2022-09-29 |
JP2023515620A (ja) | 2023-04-13 |
CR20220484A (es) | 2022-12-15 |
MX2022010683A (es) | 2023-01-19 |
IL295957A (en) | 2022-10-01 |
CL2022002342A1 (es) | 2023-03-17 |
WO2021174164A1 (en) | 2021-09-02 |
CL2022002341A1 (es) | 2023-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20210483A (es) | Polvo de aceite de cannabis formulado por nanoemulsificación, métodos de producción y usos de los mismos | |
WO2006008120A8 (de) | Wässrige bindemitteldispersion mit nanopartikeln, verfahren zu deren herstellung und deren verwendung | |
BR112017005827A2 (pt) | dispersão coloidal, método de fazer uma dispersão coloidal e catalisador | |
MX368899B (es) | Composiciones para el cuidado personal que contienen polielectrolitos formadores de complejos. | |
WO2008057245A3 (en) | Water-based skin care composition with polyalkylsilsesquioxane powder emulsion and method for making the same | |
WO2010091790A8 (en) | A compound material comprising a metal and nanoparticles and a method for producing the same | |
MY174831A (en) | Hybrid organic-inorganic nano-particles | |
EP3741362A3 (en) | Surface-modified mesoporous silica nanoparticle for blood-brain barrier penetration, tumor targeting and cancer metastasis treatment, methods of production and uses thereof | |
WO2011154905A3 (en) | Colored aqueous cosmetic compositions | |
MX2017007580A (es) | Dispersion acuosa de poliuretano-poliurea y pintura de base acuosa que contiene dicha dispersion. | |
MX2022012692A (es) | Composiciones que comprenden nanoparticulas, metodo de elaboracion y usos de las mismas. | |
DE112015005554T5 (de) | Eisen-basiertes legierungspulver für die pulvermetallurgie und ein sintergeschmiedetes bauteil | |
WO2008081905A1 (ja) | 分散組成物及びスキンケア用化粧料並びに分散組成物の製造方法 | |
WO2021226206A3 (en) | Cannabinoid receptor type 2 (cb2) modulators and uses thereof | |
GB2596625A (en) | Corrodible downhole article | |
AR123276A1 (es) | Una composición agrícola orgánica y procesos para prepararla | |
DE502007006884D1 (de) | Sedimentationsstabile dispersion, verfahren zur herstellung sowie deren verwendung | |
US20140086784A1 (en) | Process for producing a lead-free sliding bearing material | |
WO2018172430A3 (fr) | Procédé de préparation de capsules comprenant au moins un composé volatile et capsules obtenues | |
ATE390116T1 (de) | Nanopartikul res redispergierbares zinkoxidpulver | |
MX2017008787A (es) | Composiciones para el tratamiento de infecciones producidas por el acaro demodex ssp. | |
MX2021012960A (es) | Composiciones y metodos de uso de cannabinoides para neuroproteccion. | |
MX2023003308A (es) | Composicion antibacteriana hidratante. | |
WO2019123261A3 (en) | Oral compositions and methods of use | |
MX2020009886A (es) | Produccion de nanoparticulas de hidroxido de calcio y su uso como aceleradores en composiciones de aglutinantes minerales. |